OSI-774 (Erlotinib, Tarceva) in Elderly Patients

• Status: Completed
• Trial end date: 2007-01-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Collaborator: Genentech, Inc.
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Patients must have confirmed non-small cell lung cancer. Age > 65 years Patients must have adequate organ and marrow function

Exclusion Criteria:

• Patients who have had prior chemotherapy will be excluded. Patients may not be receiving any other investigational agents.